Hemab Records $0.58 Loss Per Share in Third Quarter of 2026

Hemab Therapeutics (Nasdaq: COAG) had a net loss of $27.3 million, or $0.58 per share, for the third quarter ended Sept. 30, 2026. Net loss per share was $0.58 on both basic and diluted bases. Net loss increased from $17.1 million in the third quarter of 2025. Operating expenses rose to $29.8 million from $17.1 million, while research and development expenses climbed to $24.6 million from $14.6 million. Hemab is developing therapies for blood coagulation disorders. The company released its third-quarter results Nov. 10. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.